MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Raised to $30.00 at BTIG Research

24 Feb 2026, 14:04 by Danessa Lincoln · The Markets Daily

MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) had its price target increased by BTIG Research from $24.00 to $30.00 in a research report released on Monday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts also recently issued reports on the stock. Zacks Research downgraded shares of MoonLake Immunotherapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. UBS Group set a $24.00 target price on shares of MoonLake Immunotherapeutics in a research note on Friday, January 9th. The Goldman Sachs Group lowered shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and boosted their target price for the company from $8.00 to $10.00 in a report on Wednesday, January 14th. Royal Bank Of Canada upped their price target on shares of MoonLake Immunotherapeutics from $10.00 to $12.00 and gave the company a “sector perform” rating in a research report on Friday. Finally, Citigroup lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a research report on Wednesday, October 29th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $26.77.

Get Our Latest Stock Report on MLTX

MoonLake Immunotherapeutics Stock Down 0.5%

Shares of NASDAQ:MLTX opened at $18.68 on Monday. The business has a fifty day simple moving average of $15.32 and a 200 day simple moving average of $23.85. MoonLake Immunotherapeutics has a 12-month low of $5.95 and a 12-month high of $62.75. The firm has a market cap of $1.20 billion, a P/E ratio of -5.63 and a beta of 1.20. The company has a quick ratio of 8.50, a current ratio of 8.50 and a debt-to-equity ratio of 0.25.

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.97). During the same period in the prior year, the company earned ($0.72) EPS. Analysts predict that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Insiders Place Their Bets

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 72,908 shares of the firm’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $14.43, for a total value of $1,052,062.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Da Silva Jorge Santos sold 70,000 shares of MoonLake Immunotherapeutics stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $14.49, for a total transaction of $1,014,300.00. Following the completion of the sale, the chief executive officer directly owned 2,878,577 shares of the company’s stock, valued at approximately $41,710,580.73. This trade represents a 2.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 402,908 shares of company stock valued at $5,987,162 over the last 90 days. Corporate insiders own 12.05% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MLTX. Virtu Financial LLC bought a new position in MoonLake Immunotherapeutics in the fourth quarter worth approximately $166,000. T. Rowe Price Investment Management Inc. acquired a new position in shares of MoonLake Immunotherapeutics during the fourth quarter worth approximately $47,000. Vident Advisory LLC bought a new position in shares of MoonLake Immunotherapeutics in the 4th quarter worth $204,000. Virtus Investment Advisers LLC lifted its holdings in shares of MoonLake Immunotherapeutics by 595.8% in the 4th quarter. Virtus Investment Advisers LLC now owns 17,987 shares of the company’s stock worth $237,000 after purchasing an additional 15,402 shares in the last quarter. Finally, Susquehanna Portfolio Strategies LLC acquired a new stake in MoonLake Immunotherapeutics in the 4th quarter valued at $3,347,000. 93.85% of the stock is owned by institutional investors and hedge funds.

Key MoonLake Immunotherapeutics News

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

Positive Sentiment: Topline Phase 2 S-OLARIS results showed 80% ASAS40 response at Week 12 and concordant improvements on multiple clinical and imaging endpoints; PET/MRI suggested reduced inflammation and osteoblast activity (potential disease-modifying signal). This is the primary driver of the stock move. GlobeNewswire
Positive Sentiment: Market coverage and headlines amplified the reaction — outlets reported the trial win and noted shares surged, reinforcing momentum into the investor-day webcast. Short-term trading response is tied to these reports. Investing.com
Positive Sentiment: Liquidity update: MoonLake reported ~$394M in cash and short-term securities, raised $75M in equity, and amended its Hercules loan with a $25M drawdown and up to $400M non-dilutive capacity remaining — extending runway into H2 2027 and reducing near-term financing risk. GlobeNewswire
Neutral Sentiment: Investor Day materials (slides) published — these provide management’s roadmap, program updates and commercial strategy; useful for evaluating longer-term value but are informational rather than catalytic by themselves. Seeking Alpha Slideshow
Neutral Sentiment: Investor Day transcript available for detailed read-through of management comments and Q&A; may reveal nuances on next steps, timelines and regulatory plans. Seeking Alpha Transcript
Neutral Sentiment: Quarterly results: EPS of ($0.97) met Street estimates (in-line quarter); meeting expectations reduces downside from an earnings surprise but didn’t add upside. Press Release
Negative Sentiment: RBC Capital assigned a “Hold” — a neutral-to-conservative analyst stance that could limit upside from a valuation perspective if other sell-side firms adopt cautious views. Globe & Mail

MoonLake Immunotherapeutics Company Profile

(Get Free Report)